Imugene Limited   Report issue

For profit Phase 1 Phase 2
Founded: Melbourne Australia (2012)

Organization Overview

First Clinical Trial
2016
NCT02795988
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Imugene Limited